These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 9700979)

  • 1. Effect of GR144053, a fibrinogen-receptor antagonist, on thrombus formation and vascular patency after thrombolysis by tPA in the injured carotid artery of the hamster.
    Matsuno H; Kozawa O; Niwa M; Ito T; Tanabe K; Nishida M; Hayashi H; Uematsu T
    J Cardiovasc Pharmacol; 1998 Aug; 32(2):191-7. PubMed ID: 9700979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiplatelet effect of FK633, a platelet glycoprotein IIb/IIIa antagonist, on thrombus formation and vascular patency after thrombolysis in the injured hamster carotid artery.
    Kaida T; Matsuno H; Niwa M; Kozawa O; Miyata H; Uematsu T
    Thromb Haemost; 1997 Mar; 77(3):562-7. PubMed ID: 9066011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GR144053, a fibrinogen receptor antagonist, enhances the suppression of neointima formation by losartan, an angiotensin II receptor antagonist, in the injured carotid artery of hamster.
    Matsuno H; Kozawa O; Niwa M; Kaida T; Hayashi H; Uematsu T
    Br J Pharmacol; 1997 Nov; 122(6):1099-104. PubMed ID: 9480031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the antithrombotic effects and bleeding risk of fractionated aurin tricarboxylic acid and the GPIIb/IIIa antagonist GR144053 in a hamster model of stenosis.
    Ito T; Matsuno H; Kozawa O; Niwa M; Sakai N; Uematsu T
    Thromb Res; 1999 Jul; 95(1):49-61. PubMed ID: 10403686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of tPA significantly affects antithrombotic therapy by a GPIIb/IIIa antagonist, but not by a thrombin inhibitor in mice.
    Matsuno H; Kozawa O; Ueshima S; Matsuo O; Collen D; Uematsu T
    Thromb Haemost; 2000 Apr; 83(4):605-9. PubMed ID: 10780325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. tPA, but not uPA, significantly affects antithrombotic therapy by a glycoprotein IIb/IIIa antagonist, but not by a factor Xa inhibitor.
    Nishida M; Matsuno H; Kozawa O; Ueshima S; Matsuo O; Collen D; Uematsu T
    J Cardiovasc Pharmacol; 2000 Dec; 36(6):770-5. PubMed ID: 11117378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative antiplatelet effects of aspirin, vapiprost and GR144053, a GPIIb/IIIa antagonist, with a special reference to the role of platelet microaggregates.
    Matsuno H; Kozawa O; Nagashima S; Kanamaru M; Uematsu T
    Br J Pharmacol; 1999 Jul; 127(5):1129-34. PubMed ID: 10455258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antagonism of the GPIIb/IIIa receptor with the nonpeptidic molecule BIBU52: inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo.
    Guth BD; Seewaldt-Becker E; Himmelsbach F; Weisenberger H; Müller TH
    J Cardiovasc Pharmacol; 1997 Aug; 30(2):261-72. PubMed ID: 9269956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
    Ramjit DR; Lynch JJ; Sitko GR; Mellott MJ; Holahan MA; Stabilito II; Stranieri MT; Zhang G; Lynch RJ; Manno PD
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1501-11. PubMed ID: 8371153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological properties of YM-57029, a novel platelet glycoprotein IIb/IIIa antagonist.
    Moritani Y; Sato K; Shigenaga T; Hisamichi N; Ichihara M; Akamatsu S; Suzuki Ki; Nii T; Kaku S; Kawasaki T; Matsumoto Y; Inagaki O; Tomioka K; Yanagisawa I
    Eur J Pharmacol; 2002 Mar; 439(1-3):43-52. PubMed ID: 11937091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple inhibition of platelet activation by aurintricarboxylic acid prevents vascular stenosis after endothelial injury in hamster carotid artery.
    Matsuno H; Kozawa O; Niwa M; Tanabe K; Ichimaru K; Takiguchi Y; Yokota M; Hayashi H; Uematsu T
    Thromb Haemost; 1998 Apr; 79(4):865-71. PubMed ID: 9569206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TP-9201, a glycoprotein IIb/IIIa platelet receptor antagonist, prevents rethrombosis after successful arterial thrombolysis in the dog.
    Rebello SS; Driscoll EM; Lucchesi BR
    Stroke; 1997 Sep; 28(9):1789-96. PubMed ID: 9303027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitors of fibrinolytic components play different roles in the formation and removal of arterial thrombus in mice.
    Matsuno H; Kozawa O; Okada K; Ueshima S; Matsuo O; Uematsu T
    J Cardiovasc Pharmacol; 2002 Feb; 39(2):278-86. PubMed ID: 11791014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of microsurgical thrombosis by the platelet glycoprotein IIb/IIIa antagonist SR121566A.
    Ching S; Thoma A; Monkman S; Kelton JG
    Plast Reconstr Surg; 2003 Jul; 112(1):177-85. PubMed ID: 12832891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet GPIIb/IIIa receptor inhibition by SC-49992 prevents thrombosis and rethrombosis in the canine carotid artery.
    Rote WE; Werns SW; Davis JH; Feigen LP; Kilgore KS; Lucchesi BR
    Cardiovasc Res; 1993 Mar; 27(3):500-7. PubMed ID: 8490951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of vapiprost, a novel thromboxane receptor antagonist, on thrombus formation and vascular patency after thrombolysis by tissue-type plasminogen activator.
    Matsuno H; Uematsu T; Umemura K; Takiguchi Y; Wada K; Nakashima M
    Br J Pharmacol; 1992 Jul; 106(3):533-8. PubMed ID: 1387025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of von Willebrand factor binding to platelet GP Ib by a fractionated aurintricarboxylic acid prevents restenosis after vascular injury in hamster carotid artery.
    Matsuno H; Kozawa O; Niwa M; Uematsu T
    Circulation; 1997 Aug; 96(4):1299-304. PubMed ID: 9286962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongation.
    Cook JJ; Sitko GR; Holahan MA; Stranieri MT; Glass JD; Askew BC; McIntyre CJ; Claremon DA; Baldwin JJ; Hartman GD; Gould RJ; Lynch JJ
    J Pharmacol Exp Ther; 1997 May; 281(2):677-89. PubMed ID: 9152373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model.
    Wang K; Zhou X; Huang Y; Khalil M; Wiktor D; van Giezen JJ; Penn MS
    Thromb Haemost; 2010 Sep; 104(3):609-17. PubMed ID: 20694285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined effects of a factor Xa inhibitor YM466 and a GPIIb/IIIa antagonist YM128 on thrombosis and neointima formation in mice.
    Iwatsuki Y; Kawasaki T; Hayashi K; Moritani Y; Nii T; Miyata K
    Thromb Haemost; 2004 Dec; 92(6):1221-8. PubMed ID: 15583727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.